# NCT06435429 (NCT06435429)

> A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06435429
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Jazz Pharmaceuticals
- Conditions: Metastatic HER2-positive Breast Cancer
- Interventions: Zanidatamab; Trastuzumab; Eribulin; Vinorelbine; Gemcitabine; Capecitabine
- Enrollment: 550
- Primary outcome: Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 1
- X threads: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06435429